BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2003;149:1095-1107. [PMID: 14696593 DOI: 10.1111/j.1365-2133.2003.05698.x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 182] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
2 Humphry N. An Overview of the EORTC-CLTG 2022 Congress. EMJ Oncol 2022. [DOI: 10.33590/emjoncol/10045588] [Reference Citation Analysis]
3 Xiao F, Cheng Y, Wang JR, Wang D, Zhang Y, Chen K, Mei X, Luo X. Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement. Pharmaceutics 2022;14:2198. [PMID: 36297633 DOI: 10.3390/pharmaceutics14102198] [Reference Citation Analysis]
4 Morita A, Tateishi C, Ikumi K, Hayashi D, Nakada A, Nishihara H, Torii K, Nishida E, Tsuruta D. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma. Dermatol Ther (Heidelb) 2022. [PMID: 35084694 DOI: 10.1007/s13555-021-00655-0] [Reference Citation Analysis]
5 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Hematopoietic and Lymphoid Tumors. Nonmelanocytic Tumors of the Skin 2021. [DOI: 10.55418/9781933477121-3] [Reference Citation Analysis]
7 Gru AA, Rooke B, Molloy K, Scarisbrick J. Cutaneous T‐cell Lymphoma. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch18] [Reference Citation Analysis]
8 Rattanakaemakorn P, Ploydaeng M, Udompanich S, Thadanipon K, Rutnin S, Rajatanavin N. Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study. Indian J Dermatol Venereol Leprol 2021;87:645-50. [PMID: 33871205 DOI: 10.25259/IJDVL_555_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Brouwer IJ, Out-Luiting JJ, Vermeer MH, Tensen CP. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. Biochem Biophys Rep 2020;24:100832. [PMID: 33102814 DOI: 10.1016/j.bbrep.2020.100832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol 2020;34:2693-716. [PMID: 33025659 DOI: 10.1111/jdv.16890] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
11 D'Agostino P, Kent A, Sharp E, Schmidt F, Turini M. Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description. Drugs Context 2020;9:2020-4-8. [PMID: 32821261 DOI: 10.7573/dic.2020-4-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
13 Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon Open 2020;4:563-74. [PMID: 32207075 DOI: 10.1007/s41669-020-00203-0] [Reference Citation Analysis]
14 Atci T, Baykal C. Efficacy of narrow-band ultraviolet-B therapy in patch-stage mycosis fungoides: A clinical study and review of the literature. Photodermatol Photoimmunol Photomed 2020;36:271-7. [PMID: 32145109 DOI: 10.1111/phpp.12547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, Nishida E, Tsuruta D. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. J Dermatol 2020;47:443-51. [PMID: 32189402 DOI: 10.1111/1346-8138.15310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Paul-Gunther S, Hofer A, Gruber-Wackernagel A, Legat F, Patra V, Quehenberger F, Cerroni L, Clark R, Wolf P. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial. JAMA Dermatol 2019;155:538-47. [PMID: 30892603 DOI: 10.1001/jamadermatol.2018.5905] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
17 Livesey A, Garty F, Shipman AR, Shipman KE. Lactate dehydrogenase in dermatology practice. Clin Exp Dermatol 2020;45:539-43. [PMID: 31755143 DOI: 10.1111/ced.14134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang Y, Bagot M. Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018. Br J Dermatol 2019;180:443-4. [PMID: 30821385 DOI: 10.1111/bjd.17523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Cabello I, Alia P, Pintó X, Muniesa C, Fernandez-de-Misa R, Peñate Y, Morillo M, Perez-Farriols A, Estrach T, Izu R, Gallardo F, Román C, Cervigón I, Ortiz-Brugues A, Ortiz-Romero PL, Servitje O. Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. JAMA Dermatol 2018;154:1424-31. [PMID: 30422238 DOI: 10.1001/jamadermatol.2018.3679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
21 Puffer RC, Dyck PJB, Paul P, Broski SM, Amrami KK, Spinner RJ. Putative mechanisms for spread and transformation of cutaneous T‐cell lymphoma to neurolymphomatosis. Muscle Nerve 2019;60. [DOI: 10.1002/mus.26670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Goodlad JR. Cutaneous lymphoma and important differential diagnoses: emphasis on cases with a cytotoxic phenotype. Diagnostic Histopathology 2019;25:240-248. [DOI: 10.1016/j.mpdhp.2019.04.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Riswold K, Johnson J, Weenig R. Diffuse follicular plugging. Int J Dermatol 2019;58:e189-90. [PMID: 31140589 DOI: 10.1111/ijd.14474] [Reference Citation Analysis]
24 Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant 2019;54:1525-52. [PMID: 30953028 DOI: 10.1038/s41409-019-0516-2] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 37.0] [Reference Citation Analysis]
25 Scarisbrick J, Quaglino P, Prince H, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz‐romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram‐wolff C, Battistella M, Alberti‐violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot‐barry M, Pham‐ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel‐kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon‐pennamen M, Battistella M, Climent F, Gonzalez‐barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots A, Hauben E, Bervoets A, Woei‐a‐jin F, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, Mckay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches J, Miyashiro D, Akilov O, Mccann S, Sahi H, Damasco F, Querfeld C, Folkes A, Bur C, Klemke C, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019;181:350-7. [DOI: 10.1111/bjd.17258] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
26 Scarisbrick J. Staging of Mycosis Fungoides and Sézary Syndrome: Time for an Update? EMJ Hematol 2018. [DOI: 10.33590/emjhematol/10313097] [Reference Citation Analysis]
27 Jang BS, Kim E, Kim IH, Kang HC, Ye SJ. Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution. Radiat Oncol J 2018;36:153-62. [PMID: 29983036 DOI: 10.3857/roj.2017.00542] [Reference Citation Analysis]
28 Wickenden K, Graham-Brown MPM, Veitch D, Dormer J, Bamford M, Graham-Brown RAC, Warwick G, Wagner S, Burton JO. Sézary Syndrome Presenting With Renal Involvement. Am J Kidney Dis 2018;72:890-4. [PMID: 29941220 DOI: 10.1053/j.ajkd.2018.04.013] [Reference Citation Analysis]
29 Tsang Y, Gu T, Sharma G, Raspa S, Drake B 3rd, Tan H. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat 2018;29:747-53. [PMID: 29733229 DOI: 10.1080/09546634.2018.1466026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Malveira MIB, Pascoal G, Gamonal SBL, Castañon MCMN. Folliculotropic mycosis fungoides: challenging clinical, histopathological and immunohistochemical diagnosis. An Bras Dermatol 2017;92:73-5. [PMID: 29267452 DOI: 10.1590/abd1806-4841.20175634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Holien T, Gederaas OA, Darvekar SR, Christensen E, Peng Q. Comparison between 8‐methoxypsoralen and 5‐aminolevulinic acid in killing T cells of photopheresis patients ex vivo. Lasers Surg Med 2018;50:469-75. [DOI: 10.1002/lsm.22806] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
32 Nudelmann L, Bonamigo RR. Cutaneous T-Cell Lymphoma and NK Cells. Dermatology in Public Health Environments 2018. [DOI: 10.1007/978-3-319-33919-1_17] [Reference Citation Analysis]
33 Spencer A, Gazzani P, Gadvi R, Hughes S, Stevens A, Shah F, Scarisbrick J. Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm. Br J Dermatol 2018;178:563-4. [DOI: 10.1111/bjd.15657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
35 Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016;175:23-44. [PMID: 27484275 DOI: 10.1111/bjd.14816] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
36 Smolewski P, Robak T. The discovery and development of romidepsin for the treatment of T-cell lymphoma. Expert Opin Drug Discov 2017;12:859-73. [PMID: 28641053 DOI: 10.1080/17460441.2017.1341487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
37 Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C, Ortiz-romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer 2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [Cited by in Crossref: 260] [Cited by in F6Publishing: 202] [Article Influence: 43.3] [Reference Citation Analysis]
38 Lynoora ER. SEZARY SYNDROME MIMICKING GENERALIZED PSORIASIS VULGARIS. IJTID 2017;6:59. [DOI: 10.20473/ijtid.v6i3.3134] [Reference Citation Analysis]
39 Lewis DJ, Duvic M. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides: Lewis and Duvic. Dermatologic Therapy 2017;30:e12485. [DOI: 10.1111/dth.12485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Jones E, Tonino Baldion A, Thomas C, Burrows T, Byrne N, Newton V, Aldridge S. Introduction of novel 3D-printed superficial applicators for high-dose-rate skin brachytherapy. Brachytherapy 2017;16:409-14. [DOI: 10.1016/j.brachy.2016.11.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
41 Cabello I, Servitje O, Corbella X, Bardés I, Pintó X. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clin Exp Dermatol 2017;42:276-81. [DOI: 10.1111/ced.13044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
42 Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol 2017;177:287-310. [PMID: 28220931 DOI: 10.1111/bjh.14537] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 14.0] [Reference Citation Analysis]
43 Shikama N, Miyazawa K. Cutaneous Lymphomas. Radiation Therapy for Extranodal Lymphomas 2017. [DOI: 10.1007/978-4-431-56435-5_9] [Reference Citation Analysis]
44 Scarisbrick JJ. Skin Scoring for Mycosis Fungoides and Sézary Syndrome. Agache's Measuring the Skin 2017. [DOI: 10.1007/978-3-319-32383-1_112] [Reference Citation Analysis]
45 Furue M, Kadono T. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome. J Dermatol 2015;42:941-4. [PMID: 26432429 DOI: 10.1111/1346-8138.13083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
46 Boursi B, Haynes K, Mamtani R, Yang YX. An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study. Arch Dermatol Res 2016;308:661-4. [PMID: 27613059 DOI: 10.1007/s00403-016-1684-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Devata S, Wilcox RA. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Am J Clin Dermatol 2016;17:225-37. [PMID: 26923912 DOI: 10.1007/s40257-016-0177-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
48 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
49 Ling T, Clayton T, Crawley J, Exton L, Goulden V, Ibbotson S, Mckenna K, Mohd Mustapa M, Rhodes L, Sarkany R, Dawe R, Mchenry P, Hughes J, Griffiths M, Mcdonagh A, Buckley D, Nasr I, Swale V, Duarte Williamson C, Levell N, Leslie T, Mallon E, Wakelin S, Hunasehally P, Cork M, Ungureanu S, Donnelly J, Towers K, Saunders C, Davis R, Brain A, Exton L, Mohd Mustapa M. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. Br J Dermatol 2016;174:24-55. [DOI: 10.1111/bjd.14317] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
50 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
51 Certo M, Endo Y, Ohta K, Sakurada S, Bagetta G, Amantea D. Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke. Pharmacol Res 2015;102:298-307. [PMID: 26546745 DOI: 10.1016/j.phrs.2015.10.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
52 Kato Y, Egusa C, Maeda T, Tsuboi R. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. J Dermatol Sci 2016;81:17-25. [PMID: 26596218 DOI: 10.1016/j.jdermsci.2015.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
53 van der Weyden C, Dickinson M, Bates SE, Prince HM. Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome – role of romidepsin in the current therapeutic landscape and implications for future practice. Expert Opinion on Orphan Drugs 2015;3:1231-9. [DOI: 10.1517/21678707.2015.1089169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Howell C, Douglas K, Cho G, El-ghariani K, Taylor P, Potok D, Rintala T, Watkins S. Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products: Guideline on the clinical use of apheresis procedures. Transfusion Med 2015;25:57-78. [DOI: 10.1111/tme.12205] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
55 Selman L, Beynon T, Radcliffe E, Whittaker S, Orlowska D, Child F, Harding R. ‘We're all carrying a burden that we're not sharing’: a qualitative study of the impact of cutaneous T-cell lymphoma on the family. Br J Dermatol 2015;172:1581-92. [DOI: 10.1111/bjd.13583] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
56 Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50:1037-56. [PMID: 25798672 DOI: 10.1038/bmt.2015.6] [Cited by in Crossref: 218] [Cited by in F6Publishing: 237] [Article Influence: 27.3] [Reference Citation Analysis]
57 Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and Sézary syndrome. Onco Targets Ther 2015;8:367-73. [PMID: 25678803 DOI: 10.2147/OTT.S61308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
58 Scarisbrick JJ. Skin Scoring for Mycosis Fungoides and Sézary Syndrome. Measuring the Skin 2015. [DOI: 10.1007/978-3-319-26594-0_112-1] [Reference Citation Analysis]
59 Fahy CM, Fortune A, Quinn F, McMenamin ME, Browne PV, Langabeer S, McCarron S, Hayden P, Marren P, Ni Chonghaile M, Irvine AD, Vandenberghe E, Barnes L. Development of mycosis fungoides after bone marrow transplantation for chronic myeloid leukaemia: transmission from an allogeneic donor. Br J Dermatol 2014;170:462-7. [PMID: 24116988 DOI: 10.1111/bjd.12647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
60 Hsiao Y, Wang H, Chen S, Tsai C, Yang J. Identified early stage mycosis fungoides from psoriasis and atopic dermatitis using non-invasive color contrast enhancement by LEDs lighting. Opt Quant Electron 2015;47:1599-611. [DOI: 10.1007/s11082-014-0017-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
61 Faivre L, Lecouflet L, Liu W, Khadher I, Lahaie C, Vidal M, Legouvello S, Beaumont J, Bierling P, Rouard H, Birebent B. Quality control of extracorporeal photochemotherapy: Proliferation assay using CFSE validated according to ISO 15189:2007 standards: CFSE PROLIFERATION AS A QUALITY CONTROL ASSAY FOR CELLULAR THERAPY PRODUCT. Cytometry 2015;88:30-9. [DOI: 10.1002/cyto.b.21188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
62 Li M, Sun Y, Guan X, Shu X, Li C. Advanced progress on the relationship between RA and its receptors and malignant tumors. Critical Reviews in Oncology/Hematology 2014;91:271-82. [DOI: 10.1016/j.critrevonc.2014.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
63 Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28 Suppl 1:1-37. [PMID: 24354653 DOI: 10.1111/jdv.12311] [Cited by in Crossref: 138] [Cited by in F6Publishing: 139] [Article Influence: 15.3] [Reference Citation Analysis]
64 Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:837-51. [PMID: 25042790 DOI: 10.1002/ajh.23756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
65 Humme D, Nast A, Erdmann R, Vandersee S, Beyer M. Systematic review of combination therapies for mycosis fungoides. Cancer Treat Rev 2014;40:927-33. [PMID: 24997678 DOI: 10.1016/j.ctrv.2014.06.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
66 Scarisbrick J, Kim Y, Whittaker S, Wood G, Vermeer M, Prince H, Quaglino P. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 2014;170:1226-36. [DOI: 10.1111/bjd.12909] [Cited by in Crossref: 91] [Cited by in F6Publishing: 100] [Article Influence: 10.1] [Reference Citation Analysis]
67 Laws PM, Shear NH, Pope E. Childhood mycosis fungoides: experience of 28 patients and response to phototherapy. Pediatr Dermatol. 2014;31:459-464. [PMID: 24916067 DOI: 10.1111/pde.12338] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
68 Wu P, Huang V, Bigby M. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review. Br J Dermatol 2014;170:1015-20. [DOI: 10.1111/bjd.12954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
69 Beynon T, Radcliffe E, Child F, Orlowska D, Whittaker S, Lawson S, Selman L, Harding R. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol 2014;170:599-608. [DOI: 10.1111/bjd.12644] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
70 Khan M, Scarisbrick JJ. Pediatric cutaneous lymphomas: rare diseases requiring expert diagnosis and management. Expert Review of Dermatology 2014;8:489-99. [DOI: 10.1586/17469872.2013.838041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Dubrey SW, Rosser G, Patel K, Whittaker SJ. Erythroderma is not all psoriasis: a case of Sézary syndrome. Br J Hosp Med (Lond) 2014;75:50-1. [PMID: 24401973 DOI: 10.12968/hmed.2014.75.1.50] [Reference Citation Analysis]
72 Zain J, Kaminetzky D, O’connor OA. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Review of Hematology 2014;3:187-203. [DOI: 10.1586/ehm.10.9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
73 Arava S, Singh M, Singh A. Cutaneous lymphomas: An update. Indian J Dermatopathol Diagn Dermatol 2014;1:7. [DOI: 10.4103/2349-6029.135188] [Reference Citation Analysis]
74 Baum CL, Davis DM. Lymphoproliferative Disorders. Severe Skin Diseases in Children 2014. [DOI: 10.1007/978-3-642-39532-1_13] [Reference Citation Analysis]
75 Ortiz-romero PL, Papadavid E. Systemic Treatment of Primary Cutaneous Lymphomas. Skin Cancer 2014. [DOI: 10.1007/978-1-4614-7357-2_29] [Reference Citation Analysis]
76 Abbott R, Aldridge C, Dojcinov S, Piguet V. Incidence of primary cutaneous T-cell lymphoma in Wales. Br J Dermatol 2013;169:1366-7. [DOI: 10.1111/bjd.12516] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
77 Willemze R, Hodak E, Zinzani P, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24:vi149-54. [DOI: 10.1093/annonc/mdt242] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 9.9] [Reference Citation Analysis]
78 Quéreux G, Brocard A, Saint-Jean M, Peuvrel L, Knol AC, Allix R, Khammari A, Renaut JJ, Dréno B. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013;69:890-7. [PMID: 24041738 DOI: 10.1016/j.jaad.2013.07.047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
79 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
80 Scarisbrick J, Morris S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol 2013;169:260-5. [DOI: 10.1111/bjd.12403] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
81 Morris SL, Mcgovern M, Bayne S, Wain M, Child F, Whittaker S. Results of a 5-Week Schedule of Modern Total Skin Electron Beam Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 2013;86:936-41. [DOI: 10.1016/j.ijrobp.2013.04.042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
82 Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dréno B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother 2013;14:1711-21. [PMID: 23837676 DOI: 10.1517/14656566.2013.810718] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
83 Hanna R, Di Primio GA, Schweitzer M, Torres C, Sheikh A, Chakraborty S. Progressive neurolymphomatosis with cutaneous disease: response in a patient with mycosis fungoides. Skeletal Radiol 2013;42:1011-5. [PMID: 23532558 DOI: 10.1007/s00256-013-1595-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
84 Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49:2859-2868. [PMID: 23735705 DOI: 10.1016/j.ejca.2013.04.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
85 Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013;149:25-32. [PMID: 23069814 DOI: 10.1001/2013.jamadermatol.541] [Cited by in Crossref: 104] [Cited by in F6Publishing: 110] [Article Influence: 10.4] [Reference Citation Analysis]
86 Sokołowska-Wojdyło M, Lugowska-Umer H, Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol 2013;30:19-29. [PMID: 24278042 DOI: 10.5114/pdia.2013.33375] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
87 Sharma S, Beck J, Mita M, Paul S, Woo MM, Squier M, Gadbaw B, Prince HM. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs 2013;31:974-85. [PMID: 23377661 DOI: 10.1007/s10637-013-9930-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
88 Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 2013;85:21-31. [DOI: 10.1016/j.critrevonc.2012.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
89 Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013;168:192-200. [PMID: 22963233 DOI: 10.1111/bjd.12042] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
90 Izu-belloso R, García-ruiz J. Actualización terapéutica en linfomas cutáneos. Actas Dermo-Sifiliográficas 2012;103:694-707. [DOI: 10.1016/j.ad.2012.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
91 Izu-belloso R, García-ruiz J. Treatment of Cutaneous Lymphomas: an Update. Actas Dermo-Sifiliográficas (English Edition) 2012;103:694-707. [DOI: 10.1016/j.adengl.2012.09.016] [Reference Citation Analysis]
92 Weberschock T, Strametz R, Lorenz M, Röllig C, Bunch C, Bauer A, Schmitt J. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012;:CD008946. [PMID: 22972128 DOI: 10.1002/14651858.CD008946.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
93 Kim M, Thompson LA, Wenger SD, O'bryant CL. Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma. Ann Pharmacother 2012;46:1340-8. [DOI: 10.1345/aph.1r036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
94 Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, Tokura Y, Nozaki K, Izutsu K, Suzuki R, Setoyama M, Nagatani T, Koga H, Tani M, Iwatsuki K. Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group. J Dermatol 2013;40:2-14. [DOI: 10.1111/j.1346-8138.2012.01639.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
95 Rodd AL, Ververis K, Karagiannis TC. Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. Lymphoma 2012;2012:1-10. [DOI: 10.1155/2012/290685] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
96 Duhovic C, Child F, Wain EM. Management of cutaneous T-cell lymphoma. Clin Med (Lond) 2012;12:160-4. [PMID: 22586794 DOI: 10.7861/clinmedicine.12-2-160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
97 Morris S. Skin Lymphoma. Clinical Oncology 2012;24:371-85. [DOI: 10.1016/j.clon.2012.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
98 Lyseng-Williamson KA, Yang LP. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol 2012;13:67-71. [PMID: 22066664 DOI: 10.2165/11208520-000000000-00000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
99 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2012;1:CD008908. [PMID: 22258991 DOI: 10.1002/14651858.cd008908.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
100 Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma. Oncology Times 2012;24:S1-S10. [DOI: 10.1097/01.cot.0000411497.34291.d7] [Reference Citation Analysis]
101 Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. Current Opinion in Oncology 2012;24:S1-S10. [DOI: 10.1097/01.cco.0000410158.56500.c4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
102 Yang LP. Romidepsin in the Treatment of T-Cell Lymphoma†: Profile Report. BioDrugs 2011;25:393-5. [DOI: 10.2165/11207660-000000000-00000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
103 Hristov AC, Vonderheid EC, Borowitz MJ. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome. Am J Clin Pathol 2011;136:944-53. [PMID: 22095381 DOI: 10.1309/AJCP09OTJOYAVZZK] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
104 Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leukemia & Lymphoma 2012;53:789-95. [DOI: 10.3109/10428194.2011.629701] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
105 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [PMID: 21990092 DOI: 10.1002/ajh.22139] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
106 Lee SY, Kwon HC, Cho YS, Nam KH, Ihm CW, Kim JS. The three dimensional conformal radiotherapy for hyperkeratotic plantar mycosis fungoides. Ann Dermatol 2011;23 Suppl 1:S57-60. [PMID: 22028574 DOI: 10.5021/ad.2011.23.S1.S57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Ward DM. Extracorporeal photopheresis: How, when, and why. J Clin Apheresis 2011;26:276-85. [DOI: 10.1002/jca.20300] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
108 Geddes A, Savin J, White S, Gibson J. Primary cutaneous cd8-positive t-cell lymphoma: a case report of a rare and aggressive disease with oral presentation. Dental Update 2011;38:472-6. [DOI: 10.12968/denu.2011.38.7.472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Abbott RA, Sahni D, Robson A, Agar N, Whittaker S, Scarisbrick JJ. Poikilodermatous mycosis fungoides: A study of its clinicopathological, immunophenotypic, and prognostic features. Journal of the American Academy of Dermatology 2011;65:313-9. [DOI: 10.1016/j.jaad.2010.05.041] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
110 Grover S, Verma R, Mani NS, Grewal RS, Singh GK. Primary Cutaneous T-cell Lymphoma: Two Rare Presentations. Med J Armed Forces India 2010;66:73-5. [PMID: 27365711 DOI: 10.1016/S0377-1237(10)80103-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Marta GN, Gouvêa CB, Ferreira SB, Hanna SA, Haddad CM, Silva JL. Mycosis fungoides: case report treated with radiotherapy. An Bras Dermatol 2011;86:561-4. [PMID: 21738977 DOI: 10.1590/s0365-05962011000300022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
112 Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed 2011;27:68-74. [PMID: 21392108 DOI: 10.1111/j.1600-0781.2011.00559.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
113 Yang LP. Romidepsin: In the Treatment of T-Cell Lymphoma. Drugs 2011;71:1469-80. [DOI: 10.2165/11207170-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
114 VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64:525-531. [PMID: 21587264 DOI: 10.1038/ja.2011.35] [Cited by in Crossref: 199] [Cited by in F6Publishing: 209] [Article Influence: 16.6] [Reference Citation Analysis]
115 . Neoplasms. British Association of Dermatologists' Management Guidelines 2011. [DOI: 10.1002/9781444329865.ch3] [Reference Citation Analysis]
116 Sánchez MA, González T, Gaitán MF, Zuluaga A, Jiménez SB, de Galvis YT. Is PUVA maintenance therapy necessary in patients with early-stage mycosis fungoides? Evaluation of a treatment guideline over a 28-month follow-up. Int J Dermatol 2011;50:1086-93. [PMID: 21375528 DOI: 10.1111/j.1365-4632.2010.04833.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
117 Weberschock T, Rehberger P, Röllig C, Bunch C, Schmitt J, Bauer A, Weberschock T. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
118 Brattseva EV, Rotanov SV, Bratseva EV, Rotanov SV. Current approaches to diagnostics of mycosis fungoides. Vestnik dermatologii i venerologii 2010;86:16-22. [DOI: 10.25208/vdv773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Schlaak M, Theurich S, Skoetz N, Pickenhain J, Engert A, Kurschat P, Bergwelt-baildon M. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008908] [Reference Citation Analysis]
120 Cwynarski K, Goldstone AH. Non‐Hodgkin Lymphoma. Postgraduate Haematology 2010. [DOI: 10.1002/9781444323160.ch35] [Reference Citation Analysis]
121 Rosolen A, Mussolin L. Non-Hodgkin's Lymphoma. Pediatric Hematology and Oncology 2010. [DOI: 10.1002/9781444315134.ch9] [Reference Citation Analysis]
122 Sokołowska-Wojdyło M, Trzeciak M, Roszkiewicz J. 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma. Dermatol Reports 2010;2:e12. [PMID: 25386249 DOI: 10.4081/dr.2010.e12] [Reference Citation Analysis]
123 Balogun RA, Kaplan A, Ward DM, Okafor C, Burns TM, Torloni AS, Macik BG, Abdel-rahman EM. Clinical applications of therapeutic apheresis. J Clin Apheresis 2010;25:250-64. [DOI: 10.1002/jca.20249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
124 Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492-4499. [PMID: 20697072 DOI: 10.1200/jco.2010.29.3241] [Cited by in Crossref: 144] [Cited by in F6Publishing: 157] [Article Influence: 11.1] [Reference Citation Analysis]
125 Hegde R. Radiotherapy in cutaneous anaplastic large cell lymphoma. J Cutan Aesthet Surg 2010;3:52. [PMID: 20606998 DOI: 10.4103/0974-2077.63258] [Reference Citation Analysis]
126 Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21:v177-80. [DOI: 10.1093/annonc/mdq183] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
127 Hymes KB. The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2010;10:98-109. [DOI: 10.3816/clml.2010.n.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
128 Suh KS, Kang JS, Baek JW, Kim TK, Lee JW, Jeon YS, Jang MS, Kim ST. Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases. Ann Dermatol 2010;22:1-8. [PMID: 20548873 DOI: 10.5021/ad.2010.22.1.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
129 Iwatsuki K, Kawai K, Sugaya M. Practical treatments for cutaneous malignant lymphomas : mycosis fungoides/S^|^eacute;zary syndrome. Skin Cancer 2010;25:250-262. [DOI: 10.5227/skincancer.25.250] [Reference Citation Analysis]
130 Mcgirt LY, Steinhoff M. Cutaneous Lymphomas. Managing Skin Cancer 2010. [DOI: 10.1007/978-3-540-79347-2_8] [Reference Citation Analysis]
131 Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21:860-863. [PMID: 19887465 DOI: 10.1093/annonc/mdp508] [Cited by in Crossref: 148] [Cited by in F6Publishing: 158] [Article Influence: 10.6] [Reference Citation Analysis]
132 Mestel D, Beyer M, Steinhoff M, Sterry W. Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 2009;100:18-32. [DOI: 10.1016/s0001-7310(09)73165-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
133 Piccinno R, Caccialanza M, Percivalle S. Minimal stage IA mycosis fungoides. Results of radiotherapy in 15 patients. Journal of Dermatological Treatment 2009;20:165-8. [DOI: 10.1080/09546630802516571] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
134 Scarisbrick J. Extracorporeal photopheresis: what is it and when should it be used? Clinical and Experimental Dermatology 2009;34:757-60. [DOI: 10.1111/j.1365-2230.2009.03475.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
135 Kim ST, Sim HJ, Jeon YS, Lee JW, Roh HJ, Choi SY, Kim YJ, Suh KS. Clinicopathological features and T-cell receptor gene rearrangement findings of mycosis fungoides in patients younger than age 20 years. J Dermatol 2009;36:392-402. [PMID: 19583687 DOI: 10.1111/j.1346-8138.2009.00665.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
136 Hivelin M, Siemionow M, Grimbert P, Lantieri L. Extracorporeal photopheresis: From solid organs to face transplantation. Transplant Immunology 2009;21:117-28. [DOI: 10.1016/j.trim.2009.04.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
137 Ogden S, Telfer NR. Skin cancer. Medicine 2009;37:305-8. [DOI: 10.1016/j.mpmed.2009.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
138 Willemze R, Dreyling M. Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009;20:iv115-8. [DOI: 10.1093/annonc/mdp147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
139 Sampogna F, Frontani M, Baliva G, Lombardo G, Alvetreti G, Di Pietro C, Tabolli S, Russo G, Abeni D. Quality of life and psychological distress in patients with cutaneous lymphoma. British Journal of Dermatology 2009;160:815-22. [DOI: 10.1111/j.1365-2133.2008.08992.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
140 Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. British Journal of Haematology 2009;145:84-6. [DOI: 10.1111/j.1365-2141.2009.07596.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
141 Dereure O. Place de l’électronthérapie dans la prise en charge du mycosis fongoïde : des indications à optimiser et un accès à faciliter. Annales de Dermatologie et de Vénéréologie 2009;136:235-7. [DOI: 10.1016/j.annder.2008.10.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Ferenczi K, Baron ED. Light Therapies for Cutaneous T-Cell Lymphoma. Light-Based Therapies for Skin of Color 2009. [DOI: 10.1007/978-1-84882-328-0_8] [Reference Citation Analysis]
143 Tsianakas A, Kienast A, Hoeger P. Infantile-onset cutaneous T-cell lymphoma. British Journal of Dermatology 2008;159:1338-41. [DOI: 10.1111/j.1365-2133.2008.08794.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
144 Arulogun S, Prince HM, Gambell P, Lade S, Ryan G, Eaton E, Mccormack C. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. Journal of the American Academy of Dermatology 2008;59:589-95. [DOI: 10.1016/j.jaad.2008.05.038] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
145 Pérez-barrio S, Izu R, García-ruiz J, Acebo E, Martínez De Lagrán Z, Díaz-pérez J. Trasplante autólogo de progenitores hematopoyéticos seguido de bexaroteno oral en paciente con micosis fungoide avanzada. Actas Dermo-Sifiliográficas 2008;99:560-4. [DOI: 10.1016/s0001-7310(08)74742-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600-1609. [PMID: 18567836 DOI: 10.1182/blood-2008-04-152850] [Cited by in Crossref: 312] [Cited by in F6Publishing: 330] [Article Influence: 20.8] [Reference Citation Analysis]
147 Bagot M. Structuration d’un réseau national et d’une réunion de concertation pluridisciplinaire nationale de recours pour la prise en charge des lymphomes cutanés rares. Oncologie 2008;10:433-436. [DOI: 10.1007/s10269-008-0892-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Scarisbrick J, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S; on behalf of the Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158:659-78. [DOI: 10.1111/j.1365-2133.2007.08415.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 8.5] [Reference Citation Analysis]
149 Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597-604. [PMID: 18176611 DOI: 10.1038/sj.bmt.1705968] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 6.0] [Reference Citation Analysis]
150 Pérez-barrio S, Izu R, García-ruiz J, Acebo E, Martínez de Lagrán Z, Díaz-pérez J. Autologous Hematopoietic Stem Cell Transplantation Followed by Oral Bexarotene in a Patient With Advanced Mycosis Fungoides. Actas Dermo-Sifiliográficas (English Edition) 2008;99:560-564. [DOI: 10.1016/s1578-2190(08)70314-7] [Reference Citation Analysis]
151 Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Gonzalez M, Huerta-guzmán J. Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals 2007;22:836-40. [DOI: 10.1089/cbr.2007.0402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
152 Karenko L, Hahtola S, Ranki A. Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL). Cytogenet Genome Res 2007;118:353-61. [DOI: 10.1159/000108320] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
153 Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R, Ranki A, Stadler R, Whittaker S. Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what? European Journal of Cancer 2007;43:2321-9. [DOI: 10.1016/j.ejca.2007.06.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
154 Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007;157:433-40. [DOI: 10.1111/j.1365-2133.2007.07975.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 6.8] [Reference Citation Analysis]
155 Lam J, Pope E. Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma. Current Opinion in Pediatrics 2007;19:441-5. [DOI: 10.1097/mop.0b013e328224b7c3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
156 Panwalkar AW, Armitage JO. T-cell/NK-cell lymphomas: A review. Cancer Letters 2007;253:1-13. [DOI: 10.1016/j.canlet.2006.11.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
157 Bertele' V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, Garattini S. Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol 2007;63:713-9. [PMID: 17530236 DOI: 10.1007/s00228-007-0296-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
158 Coronel-pérez I, Carrizosa-esquivel A, Camacho-martínez F. Tratamiento con UVB de banda estrecha de los estadios iniciales de la micosis fungoide. Estudio de 23 pacientes. Actas Dermo-Sifiliográficas 2007;98:259-64. [DOI: 10.1016/s0001-7310(07)70059-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
159 Kadin ME. Cutaneous T-Cell Lymphomas and Rare T-Cell Non-Hodgkin Lymphomas. Pediatric Lymphomas. [DOI: 10.1007/978-3-540-68753-5_10] [Reference Citation Analysis]
160 Fassihi H, White I. Diseases of the skin. Medicine and Surgery 2007. [DOI: 10.1016/b978-0-443-07260-4.50022-0] [Reference Citation Analysis]
161 Coronel-pérez I, Carrizosa-esquivel A, Camacho-martínez F. Narrow Band UVB Therapy in Early Stage Mycosis Fungoides. A Study of 23 Patients. Actas Dermo-Sifiliográficas (English Edition) 2007;98:259-264. [DOI: 10.1016/s1578-2190(07)70439-0] [Reference Citation Analysis]
162 Scarisbrick J. Treatment of mycosis fungoides and Sézary syndrome: recent advances and novel therapies. Expert Review of Dermatology 2006;1:569-577. [DOI: 10.1586/17469872.1.4.569] [Reference Citation Analysis]
163 Gokdemir G, Barutcuoglu B, Sakiz D, Koslu A. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes. J Eur Acad Dermatol Venerol 2006;0:060606020924006-???. [DOI: 10.1111/j.1468-3083.2006.01635.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
164 Ortiz-romero PL, Elena Sánchez-largo M, Sanz H, García-romero D, Rosales B, Valverde R, Arrue I, Polo I, Ruiz D, Fernández-herrera J, Vanaclocha F. Tratamiento de micosis fungoide con PUVA más bexaroteno. Actas Dermo-Sifiliográficas 2006;97:311-8. [DOI: 10.1016/s0001-7310(06)73408-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
165 Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion: Minimizing side-effects of bexarotene in CTCL. British Journal of Dermatology 2006;155:261-6. [DOI: 10.1111/j.1365-2133.2006.07329.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
166 Perez A, Whittaker S. Cutaneous T-cell lymphoma. Br J Hosp Med (Lond) 2006;67:178-83. [PMID: 16681303 DOI: 10.12968/hmed.2006.67.4.20862] [Reference Citation Analysis]
167 Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, D’Incan M, Ranki A, Pimpinelli N, Ortiz-Romero P. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42:1014-1030. [PMID: 16574401 DOI: 10.1016/j.ejca.2006.01.025] [Cited by in Crossref: 298] [Cited by in F6Publishing: 314] [Article Influence: 17.5] [Reference Citation Analysis]
168 Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 2006;31:181-6. [DOI: 10.1111/j.1365-2230.2005.02019.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
169 Sanches Jr JA, Moricz CZMD, Festa Neto C. Processos linfoproliferativos da pele: parte 2 - linfomas cutâneos de células T e de células NK. An Bras Dermatol 2006;81:7-25. [DOI: 10.1590/s0365-05962006000100002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
170 Ko CJ. The New World Health Organization–European Organization for Research and Treatment of Cancer Classification of Cutaneous Lymphomas. Advances in Dermatology 2006;22:259-77. [DOI: 10.1016/j.yadr.2006.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
171 Carr R, Sanders D. Inflammatory dermatoses mimicking malignancy (pseudolymphoma). Current Diagnostic Pathology 2005;11:245-252. [DOI: 10.1016/j.cdip.2005.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
172 Mcfarlane V, Friedmann P, Illidge T. What's new in the management of cutaneous T-cell lymphoma? Clinical Oncology 2005;17:174-84. [DOI: 10.1016/j.clon.2004.11.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
173 Piccinno R, Caccialanza M, Berti E, Vezzoli P. Role of Radiotherapy in Primary CD30+ and Pleomorphic Small/Medium-sized T-cell Lymphomas. Acta Dermato-Venereologica 2005;-1:1-1. [DOI: 10.1080/00015550410024715] [Reference Citation Analysis]
174 . Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. British Journal of Dermatology 2005;152:193-4. [DOI: 10.1111/j.1365-2133.2005.06360.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
175 Gallardo F, Pujol RM. Diagnóstico y tratamiento de los linfomas cutáneos de células T primarios. Actas Dermo-Sifiliográficas 2004;95:473-90. [DOI: 10.1016/s0001-7310(04)76864-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
176 Carrascosa JM. Fototerapia y fotoquimioterapia. Actas Dermo-Sifiliográficas 2004;95:259-84. [DOI: 10.1016/s0001-7310(04)76817-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
177 Scarisbrick J, Whittaker S, Wotherspoon A, Rosenwald A, Ott G. Cutaneous lymphoma. Lymphoma: Pathology, Diagnosis and Treatment 2001. [DOI: 10.1017/cbo9780511663369.017] [Reference Citation Analysis]
178 Hönigsmann H, Tanew A. Photo(chemo)therapy for Cutaneous T-Cell Lymphoma. In: Hönigsmann H, Elmets CA, Krutmann J, editors. Dermatological Phototherapy and Photodiagnostic Methods. Berlin: Springer Berlin Heidelberg; 2009. pp. 135-49. [DOI: 10.1007/978-3-540-36693-5_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]